Biothera’s Imprime PGG in combination with cetuximab, carboplatin and paclitaxel has met all the endpoints in a Phase II non small cell lung cancer clinical trial.
Imprime PGG is an immunomodulatory drug, used as a treatment for cancer.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The open label multicentre randomised trial enrolled 90 patients to evaluate the safety and efficacy of Imprime PGG along with cetuximab and a standard chemotherapy regimen (carboplatin and paclitaxel) compared to cetuximab alone with the same chemotherapy.
The aim of the study is to assess the anti-tumour effects of Imprime PGG with cetuximab and standard chemotherapy, based on overall response rate as evaluated by the RECIST trial.
In pre-clinical cancer models, Imprime PGG has been found to reduce tumour growth and enhance long-term survival by killing neutrophils.
Imprime PGG is being investigated in a Phase III trial in KRAS wild-type colorectal cancer and several Phase II clinical trials in non small cell lung cancer and chronic lymphocytic leukaemia.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
